Have a personal or library account? Click to login
Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica Cover

Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica

Open Access
|Jul 2013

Abstract

Background. The purpose of the study was to evaluate the correlation between the maximum standardized uptake value (SUVmax), size of primary lung lesion, disease-free survival (DFS) and overall survival (OS) in patients with stage I and II non-small cell lung cancer (NSCLC) in 2 years follow-up.

Patients and methods. Forty-nine patients with stage I-II NSCLC were included in this study. Pre-surgical 2-deoxy- 2-[18F]fluoro-D-glucose positron-emission tomography (18F-FDG PET/CT) study was performed for all patients. The relationship between SUVmax, tumour size and clinical outcome was measured. The cut-off value for SUVmax and tumour size with the best prognostic significance, probability of DFS and the correlation between SUVmax and the response to therapy were calculated.

Results. There was a statistically significant correlation between SUVmax and DFS (p = 0.029). The optimal cut-offs were 9.00 for SUVmax (p = 0.0013) and 30mm for tumour size (p = 0.0028). Patients with SUVmax > 9 and primary lesion size > 30 mm had an expected 2years-DFS of 37.5%, while this rose to 90% if the tumour was <30 mm and/or SUVmax was <9.

Conclusions. In stage I-II, SUVmax and tumour size might be helpful to identify the subgroup of patients with high chance for recurrence.

DOI: https://doi.org/10.2478/raon-2013-0023 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 219 - 223
Published on: Jul 30, 2013
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2013 Angelina Cistaro, Natale Quartuccio, Alireza Mojtahedi, Piercarlo Fania, Pier Luigi Filosso, Alfredo Campenni, Umberto Ficola, Sergio Baldari, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.